What is the share price of Valiant Laboratories Ltd (VALIANTLAB) today?
The share price of VALIANTLAB as on 5th December 2025 is ₹65.06. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Valiant Laboratories Ltd (VALIANTLAB) share?
The past returns of Valiant Laboratories Ltd (VALIANTLAB) share are- Past 1 week: -7.26%
- Past 1 month: -20.76%
- Past 3 months: -24.92%
- Past 6 months: -35.50%
- Past 1 year: -40.72%
- Past 3 years: N/A%
- Past 5 years: -59.16%
What are the peers or stocks similar to Valiant Laboratories Ltd (VALIANTLAB)?
The peers or stocks similar to Valiant Laboratories Ltd (VALIANTLAB) include:What is the market cap of Valiant Laboratories Ltd (VALIANTLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Valiant Laboratories Ltd (VALIANTLAB) is ₹350.70 Cr as of 5th December 2025.What is the 52 week high and low of Valiant Laboratories Ltd (VALIANTLAB) share?
The 52-week high of Valiant Laboratories Ltd (VALIANTLAB) is ₹120.92 and the 52-week low is ₹63.86.What is the PE and PB ratio of Valiant Laboratories Ltd (VALIANTLAB) stock?
The P/E (price-to-earnings) ratio of Valiant Laboratories Ltd (VALIANTLAB) is -157.97. The P/B (price-to-book) ratio is 1.50.Which sector does Valiant Laboratories Ltd (VALIANTLAB) belong to?
Valiant Laboratories Ltd (VALIANTLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Valiant Laboratories Ltd (VALIANTLAB) shares?
You can directly buy Valiant Laboratories Ltd (VALIANTLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Valiant Laboratories Ltd
VALIANTLAB Share Price
65.060.76% (+0.49)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
VALIANTLAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
VALIANTLAB Performance & Key Metrics
VALIANTLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 69.03 | 1.50 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
VALIANTLAB Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VALIANTLAB Company Profile
Valiant Laboratories Limited specializes in manufacturing pharmaceutical intermediates, particularly paracetamol API.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
VALIANTLAB Forecast
VALIANTLAB Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
VALIANTLAB
VALIANTLAB
Income
Balance Sheet
Cash Flow
Annual Normal View
VALIANTLAB Income Statement
VALIANTLAB Income Statement
Annual Normal View
| Financial Year | FY 2023 | FY 2024 | FY 2025 | TTM | ||||
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 338.77 | 191.74 | 138.81 | 186.83 | ||||
Raw Materials | 276.76 | 168.67 | 112.21 | 179.11 | ||||
| Power & Fuel Cost | 7.37 | 8.33 | 5.94 | |||||
| Employee Cost | 4.61 | 4.31 | 4.39 | |||||
| Selling & Administrative Expenses | 3.73 | 2.69 | 2.65 | |||||
| Operating & Other expenses | 6.35 | 6.46 | 12.88 | |||||
EBITDA | 39.95 | 1.28 | 0.74 | 7.72 | ||||
| Depreciation/Amortization | 1.56 | 1.97 | 2.09 | 2.10 | ||||
| PBIT | 38.39 | -0.69 | -1.35 | 5.62 | ||||
| Interest & Other Items | 0.25 | 0.08 | 0.18 | 0.32 | ||||
| PBT | 38.14 | -0.77 | -1.53 | 5.30 | ||||
| Taxes & Other Items | 9.14 | -1.09 | 0.69 | 0.22 | ||||
| Net Income | 29.00 | 0.32 | -2.22 | 5.08 | ||||
| EPS | 8.27 | 0.08 | -0.47 | 1.09 | ||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 |
VALIANTLAB Company Updates
VALIANTLAB Stock Peers
VALIANTLAB Past Performance & Peer Comparison
VALIANTLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Valiant Laboratories Ltd | -157.97 | 1.50 | — |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
VALIANTLAB Stock Price Comparison
Compare VALIANTLAB with any stock or ETFCompare VALIANTLAB with any stock or ETF
VALIANTLAB
VALIANTLAB Holdings
VALIANTLAB Shareholdings
VALIANTLAB Promoter Holdings Trend
VALIANTLAB Promoter Holdings Trend
VALIANTLAB Institutional Holdings Trend
VALIANTLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VALIANTLAB Shareholding Pattern
VALIANTLAB Shareholding Pattern
VALIANTLAB Shareholding History
VALIANTLAB Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing VALIANTLAB stock
smallcases containing VALIANTLAB stock
Looks like this stock is not in any smallcase yet.
VALIANTLAB Events
VALIANTLAB Events
VALIANTLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VALIANTLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VALIANTLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VALIANTLAB has not given any dividends in last 5 years
VALIANTLAB Dividends
VALIANTLAB Dividends
Hmm, looks like data is unavailable here. Please come back after some timeVALIANTLAB Stock News & Opinions
VALIANTLAB Stock News & Opinions
Articles & Videos
Earnings
Valiant Laboratories reports consolidated net profit of Rs 0.20 crore in the September 2025 quarter
Net profit of Valiant Laboratories reported to Rs 0.20 crore in the quarter ended September 2025 as against net loss of Rs 4.74 crore during the previous quarter ended September 2024. Sales rose 115.08% to Rs 46.20 crore in the quarter ended September 2025 as against Rs 21.48 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales46.2021.48 115 OPM %0.15-31.38 - PBDT0.81-3.39 LP PBT0.28-3.91 LP NP0.20-4.74 LP Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Valiant Laboratories to table results
Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Valiant Laboratories AGM scheduled
Valiant Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 25 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Valiant Laboratories reports consolidated net profit of Rs 1.82 crore in the June 2025 quarter
Net profit of Valiant Laboratories reported to Rs 1.82 crore in the quarter ended June 2025 as against net loss of Rs 0.51 crore during the previous quarter ended June 2024. Sales rose 147.99% to Rs 46.82 crore in the quarter ended June 2025 as against Rs 18.88 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales46.8218.88 148 OPM %5.10-12.61 - PBDT2.980.37 705 PBT2.45-0.16 LP NP1.82-0.51 LP Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Valiant Laboratories to hold board meeting
Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 8 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Valiant Laboratories to convene board meeting
Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 9 July 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Valiant Laboratories reports consolidated net profit of Rs 0.70 crore in the March 2025 quarter
Net profit of Valiant Laboratories reported to Rs 0.70 crore in the quarter ended March 2025 as against net loss of Rs 1.24 crore during the previous quarter ended March 2024. Sales rose 88.92% to Rs 57.79 crore in the quarter ended March 2025 as against Rs 30.59 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 2.20 crore in the year ended March 2025 as against net profit of Rs 0.32 crore during the previous year ended March 2024. Sales declined 26.74% to Rs 133.38 crore in the year ended March 2025 as against Rs 182.06 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales57.7930.59 89 133.38182.06 -27 OPM %6.61-14.81 --3.50-4.62 - PBDT1.46-2.05 LP 0.581.20 -52 PBT0.94-2.57 LP -1.51-0.77 -96 NP0.70-1.24 LP -2.200.32 PL Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Valiant Laboratories to discuss results
Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Valiant Laboratories reports consolidated net profit of Rs 2.35 crore in the December 2024 quarter
Net profit of Valiant Laboratories reported to Rs 2.35 crore in the quarter ended December 2024 as against net loss of Rs 3.50 crore during the previous quarter ended December 2023. Sales declined 13.06% to Rs 35.23 crore in the quarter ended December 2024 as against Rs 40.52 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales35.2340.52 -13 OPM %1.76-15.57 - PBDT2.14-4.55 LP PBT1.62-5.04 LP NP2.35-3.50 LP Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Valiant Laboratories to hold board meeting
Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant